Bevacizumab for Primary Pterygium Treatment

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study was to investigate the efficacy and safety of subconjunctival bevacizumab application as an adjuvant therapy for primary pterygium.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients with primary pterygium

Exclusion Criteria:

• Patients with diabetes mellitus

• collagenopathies,

• previous ocular surgeries,

• pregnant or lactating patients